Key Financial Figures
Consolidated Financial Results for FY2026:
- Revenue: ₹7,728 million
- Profit After Tax: ₹1,014 million (31% growth year-on-year)
- Includes fair valuation gain of investment in Apulki Healthcare Private Limited: ₹221.75 million
- Diluted EPS: ₹30.88 (31% improvement over prior year)
- Operating cash flow: ₹1,431 million (64% improvement from ₹873 million in FY2025)
Dividend Declaration
- Board recommended final dividend of ₹2 per share
- Face value of shares: ₹5
Strategic and Operational Highlights
Management Commentary from Yash Mutha, Managing Director:
- FY2026 described as "year of deliberate and disciplined investment" into long-term architecture
- PAT of ₹1,014 million represents highest reported PAT in company's history since listing
- Strong operating cash flow improvement demonstrates structural improvement in collections framework and working capital management
- Growth roadmap anchored in long-term PPP contracts, scaling B2C vertical, and entry into tertiary care through Apulki Healthcare
Management Commentary from Mitesh Dave, Group CEO:
- Retail diagnostics vertical (Krsnaa Retail Private Limited) achieved 8 times revenue growth in twelve months
- Retail touchpoints increased 7 times to 3,500 locations across 5 states
- Retail vertical established as "structurally important and independently scalable growth engine"
- Focus for FY2027 remains on disciplined execution, transparency, and strong governance standards